How to Buy Cellebrite DI Stock
Cellebrite DI Ltd
Cellebrite DI Ltd. delivers specialized digital intelligence solutions crafted for legally authorized investigations.
Cellebrite DI stock last closed at $13.76, up 8.95% from the previous day, and has decreased 15.63% in one year. It has overperformed other stocks in the Software - Infrastructure industry by 0.66 percentage points. Cellebrite DI stock is currently +24.86% from its 52-week low of $11.02, and -31.13% from its 52-week high of $19.98.
At the moment, there are 246.47M CLBT shares outstanding. The market capitalization of CLBT is $3.39B. In the last 24 hours, 3.1M CLBT shares were traded.
How to Buy Cellebrite DI Stock
Wondering how to invest in Cellebrite DI stock? Here's how.
- Decide where to buy Cellebrite DI stock: You need to pick an online brokerage, but don't worry - we've tried dozens of stock brokerages and apps to help you figure out where to buy Cellebrite DI stock.
- Open your brokerage account: Sign up for 0% fee trading with the highest-rated brokerage we've found.
- Deposit funds into your investment account: Pick your payment method and add your details.
- Analyze Cellebrite DI stock: The Cellebrite DI ticker symbol is CLBT. Is Cellebrite DI stock a good investment? Should you buy shares of CLBT? How do CLBT's underlying business fundamentals look? Do top analysts think Cellebrite DI is a good buy? Why has CLBT's stock price moved recently? (Hint: Our stock analysis website can help you evaluate if CLBT is a good stock to buy).
- Place your CLBT trade: Decide if you will purchase CLBT shares at the current market price or use a limit order to purchase CLBT shares at a particular price.
- Get the latest news on your CLBT investment: Create a watchlist to important updates regarding your investment in Cellebrite DI stock.
Step 1: Decide where to buy Cellebrite DI stock
You need a brokerage account to access the NASDAQ market and buy CLBT stock.
Our preferred brokerage: eToro
Based on our research, eToro is the best stock brokerage. eToro gives you:
- Invest in stocks with 0% commissions: Invest without paying trading commissions.
- Buy fractional shares: Even if you don't have the money to buy a full share, you can still purchase the stock.
- Access to global markets: From Technology to Industrials, New York to Shanghai (for US users, only US stocks are available) — you can fill your portfolio with stocks from the globe's top exchanges.
- Social investing: eToro boasts a community with more than 20 million users around the world. Talk to, learn from, and copy the crypto trades of other investors.
- Security: eToro is a regulated and licensed brokerage platform.
- Buy other financial assets: Such as ETFs and cryptos.
Get $10 towards your purchase of stock by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountStep 2: Open your brokerage account
Now that you've picked the best brokerage, you need to fill out some personal details so you are able to buy CLBT today.
How to Open a New Brokerage Account on eToro
- Click here to get started.eToro is a multi-asset investment platform. The value of your investments may go up or down. Your capital is at risk.
- Enter your personal info to create your new brokerage account.
- Send your data by hitting the "Create Account" button. Get started with eToro today
Step 3: Deposit funds into your investment account
Now that you have created your account on investing apps, your next step is to transfer the money for your investment:
Watch this video walkthrough for more details depositing funds into your new brokerage account.
Step 4: Analyze Cellebrite DI stock
After you have selected the best place to buy Cellebrite DI stock, it's critical to evaluate their stock before you invest, so you can understand the risk as well as the upside.
Cellebrite DI quick stats
CLBT Overview
WallStreetZen was designed to help part-time investors do more accurate fundamental analysis in less time.
You can view all of the due diligence checks on CLBT's stock page.
Is CLBT stock properly valued?
Investors use a variety of different financial metrics, analyses, models, and charts to gauge CLBT's true value.
Using relative valuations ratios:
- CLBT may be undervalued based on its P/E ratio of 49.14x, relative to Software - Infrastructure industry P/E ratio of -239.01x
- CLBT could be undervalued based on its P/B ratio of 6.64x, relative to Software - Infrastructure industry P/B ratio of 7.34x
- CLBT may be overvalued based on its PEG ratio of 1.15x
You can access additional valuation research on CLBT's stock here.
CLBT Financial Overview
Passed Health Checks:
- Total CLBT debt is lower than 5 years ago, relative to shareholder equity.
- CLBT profit margin has gone up from -46.3% to 14.5% in the past year.
- There are more short-term assets than long-term liabilities on the CLBT balance sheet.
- CLBT's operating cash flow of $172.55M allows it to safely service it's debt of $22.81M.
- There are more short-term assets than short-term liabilities on the CLBT balance sheet.
- CLBT earnings of $63.33M is not sufficient to cover its interest payments.
Failed Health Checks:
- CLBT has a relatively high debt to equity ratio of 0.87.
Do analysts think it's a good time to buy Cellebrite DI stock
Out of 2 sell side analysts who monitor CLBT, the consensus analyst rating on Cellebrite DI is a Strong Buy
Please keep in mind that analyst forecasts are not stock recommendations, nor are they financial advice.
You can dive deeper into what analysts are forecasting on the Cellebrite DI stock forecast page.
Metrics for Advanced CLBT Traders
Is CLBT Growing Revenue?
Last year, CLBT earnings were $71.86M. Over the past 5 year, CLBT's earnings have grown by 57.38% per year. This was faster than the Software - Infrastructure industry average of 36.84%.
Last year, CLBT revenue was $496.43M. During the last five year, CLBT's revenue has gone up by 24.84% per year. This was faster than the Software - Infrastructure industry average of 19.23%.
You can analyze CLBT's earnings and revenue performance here.
Latest Insiders Trades at CLBT
Over the past 12 months, executives and large shareholders at CLBT have sold more shares than they have bought.
David Nicholas Gee, Chief Marketing Officer of CLBT, was the latest CLBT insider to sell. They sold $29,383.30 worth of CLBT stock on May 21, 2026.
Learn more about who owns CLBT stock here.
Can I get consistent income from CLBT stock?
No, Cellebrite DI doesn't provide an income stream by paying out dividends.
What do other investors have to say about CLBT?
One of the biggest reasons eToro is our favorite brokerage is because of its social trading community.
Click below to see what other investors have to say.
Step 5: Place your CLBT trade
There are two primary options:
- Market order: A market order is an order to buy or sell a security at the best available price.
Market orders are mostly fine for most investors. - Limit order: A limit order enables you to buy or sell a security at a specific price (or better).
If you want to make sure you're buying or selling at a particular price, place a limit order.
Click the Open Trade button and eToro will execute your order.
If you require more info about buying stocks on eToro, click the helpful video below:
Step 6: Get the latest news on your CLBT investment
Now that you own some CLBT shares, you'll want to stay up-to-date on your new investment.
Make a watchlist to see the latest developments about your CLBT stock.
CLBT Feed
How to Buy Stock in Cellebrite DI
To summarize, here are the 6 steps you need to take to buy Cellebrite DI stock right now:
- Decide where to buy Cellebrite DI stock
- Open your brokerage account
- Deposit funds into your investment account
- Analyze Cellebrite DI stock
- Place your CLBT trade
- Get the latest news on your CLBT investment
If you require a brokerage account, eToro is our recommended venue.
Get Started with eToro TodayIf you want to track your investment in Cellebrite DI, click the button below.
Trending Articles
FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterInformation is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.